Avara Pharmaceutical Services Acquires Major Sterile Manufacturing Facility and Development Center in Canada

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

NORWALK, Conn., May 25, 2018 /PRNewswire/ -- Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), today announced that it has agreed to acquire the largest sterile manufacturing facility for injectable medicines in Canada from a leading global pharmaceutical company, as part of a continuing expansion of its global footprint.

Metadata
Provider: 
PR NewswirePR Newswire
Retrieved on: 
Friday, May 25, 2018
Information
Tags: 
Health, Pharmaceutical industry, Pfizer, Contract manufacturing organization, Software, Avara
Geotags: 
Connecticut
Organisation: 
AVARA PHARMACEUTICAL SERVICES, INC.
Website: 
http://www.avara.com
Summary
Key Points: 
  • NORWALK, Conn., May 25, 2018 /PRNewswire/ -- Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), today announced that it has agreed to acquire the largest sterile manufacturing facility for injectable medicines in Canada from a leading global pharmaceutical company, as part of a continuing expansion of its global footprint.
  • It follows Avara's acquisition of another sterile facility in the past year, one from Pfizer Inc. in Liscate, Italy, and one solid dose manufacturing facility from GlaxoSmithKline in Aiken, South Carolina.
  • Avara Pharmaceutical Services, Inc., based inNorwalk, Connecticutis an international pharmaceutical services company that delivers world-class contract manufacturing and technical services to the pharmaceutical industry.
  • Avara has primary and secondary manufacturing facilities inNorth AmericaandEuropeand supplies products to all major markets around the world.


Avara Pharmaceutical Services Acquires Major Sterile Manufacturing Facility and Development Center in Canada

NORWALK, Conn., May 25, 2018 /PRNewswire/ -- Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), today announced that it has agreed to acquire the largest sterile manufacturing facility for injectable medicines in Canada from a leading global pharmaceutical company, as part of a continuing expansion of its global footprint.

Tim Tyson, a global leader in the pharmaceutical industry, is Chairman and CEO of Avara Pharmaceutical Services. In his 35-plus year career, Mr. Tyson has negotiated complex multi-billion dollar mergers and acquisitions, led major turn-arounds that have fueled growth and value and, most significantly, has been instrumental in bringing more than 50 lifesaving and life improving medicines to the market.

"This acquisition represents our first entry into the Canadian market and further expands our sterile processing capability, which is in very high demand," said Timothy C. Tyson, Avara's Chairman and Chief Executive Officer. "It comes with a world-class development center and a dedicated team of experts that will support us in delivering high-quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements."

The proposed acquisition of Novartis Technical Operations' sterile manufacturing facility and the adjacent Sandoz Development Center located on the Sandoz Canada campus in Boucherville, Quebec, is expected to be finalized in the next few months, following the completion of a number of closing conditions including receipt of anti-trust approvals. It follows Avara's acquisition of another sterile facility in the past year, one from Pfizer Inc. in Liscate, Italy, and one solid dose manufacturing facility from GlaxoSmithKline in Aiken, South Carolina. It will bring the number of manufacturing and development sites operated by Avara worldwide to ten: two in Canada; three in the United States, including corporate headquarters; one in Puerto Rico; one in the UK; one in Ireland; one in Italy; and one in France.

The Boucherville site is the biggest injectables production facility in Canada and provides a number of strategic and lifesaving medicines to the Canadian healthcare system, mostly hospitals. As part of the asset purchase agreement, the parties have committed to sign a long-term supply contract to guarantee continuous supply of products manufactured in Boucherville. No impact on jobs is anticipated at the moment and Avara intends to invest in the site and pursue business development opportunities to optimize the plant's utilization and expand its customer base.

"We look forward to a seamless transition for employees, patients, customers, partners and other stakeholders," added Mr. Tyson. "We are impressed by the know-how at the Boucherville plant and Sandoz Development Center team and intend to leverage their expertise to develop new opportunities in the contract pharmaceutical market, in Canada and elsewhere." 

About Avara
Avara Pharmaceutical Services, Inc., based in Norwalk, Connecticut is an international pharmaceutical services company that delivers world-class contract manufacturing and technical services to the pharmaceutical industry. Avara has primary and secondary manufacturing facilities in North America and Europe and supplies products to all major markets around the world. Avara's broad experience with supply chain, commercialization, product launch and product transfer allow us to sustain exemplary levels of product quality and regulatory compliance. The company is known to exceed customer service level expectations and consistently deliver on time, in full at a fair price. For more information, please visit our website at www.avara.com.

CONTACT: Guy Tiene, (+1) 212-366-4455

Avara Pharmaceutical Services, Inc. (PRNewsfoto/Avara Pharmaceutical Services,)

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/avara-pharmaceutical-services-acquires-major-sterile-manufacturing-facility-and-development-center-in-canada-300654792.html

SOURCE Avara Pharmaceutical Services, Inc.

Copyright: 
2018 PR Newswire. All Rights Reserved.